Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
24 studies found for:    VITAL-COG
Show Display Options
Rank Status Study
1 Active, not recruiting A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline
Condition: Cognitive Decline
Interventions: Dietary Supplement: vitamin D3;   Drug: omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
2 Completed
Has Results
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
Condition: Vascular Dementia
Interventions: Drug: Cerebrolysin;   Drug: 0.9% Saline Solution
3 Completed
Has Results
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: Cerebrolysin + donepezil;   Drug: Cerebrolysin + placebo;   Drug: Donepezil + placebo
4 Completed An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Condition: Alzheimer Disease
Intervention: Drug: NS 2330 (Tesofensine)
5 Completed Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
Condition: Lewy Body Disease
Intervention: Drug: Galantamine
6 Completed A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease
Conditions: Alzheimer Disease;   Dementia;   Mental Disorders;   Brain Diseases
Intervention: Drug: galantamine hydrobromide
7 Completed An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine
Condition: Mild Cognitive Impairment
Intervention: Other: No intervention
8 Not yet recruiting Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
Condition: Alzheimer Disease
Interventions: Drug: Cerebrolysin;   Drug: Donepezil
9 Terminated A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
Condition: Alzheimer's Disease
Intervention: Drug: ABT-089
10 Completed Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: ACC-001;   Other: QS-21
11 Recruiting Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
Conditions: Mild Cognitive Impairment;   Alzheimer Disease
Interventions: Drug: Allopregnanolone injection (intravenous solution);   Drug: Placebo injection (intravenous solution)
12 Completed Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001;   Other: QS-21;   Other: PBS
13 Terminated Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: ACC-001
14 Withdrawn A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia;   Dimebon;   Investigational Drug
Interventions: Drug: PF-01913539 5 mg;   Drug: Placebo
15 Completed A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 10 mg/kg;   Biological: PF-04360365 7.5 mg/kg;   Drug: placebo
16 Completed A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: EHT 0202 etazolate;   Drug: Placebo
17 Completed Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 0.1 mg/kg;   Biological: PF-04360365 0.5 mg/kg;   Biological: PF-04360365 1 mg/kg;   Drug: Placebo;   Biological: PF-04360365 3 mg/kg;   Biological: PF-04360365 8.5 mg/kg
18 Completed ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Mixed salts of a single-entity amphetamine;   Drug: Atomoxetine hydrochloride
19 Completed A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
Conditions: Dementia;   Alzheimer Disease
Intervention: Drug: Galantamine hydrobromide
20 Completed Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: GSK239512;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years